Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I single‐institution escalation study of front‐line treatment with R‐CHOP and TAK‐659 in treatment‐naïve high‐risk DLBCL. Methods: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Karmali, Reem, St‐Pierre, Frederique, Ma, Shuo, Foster, Kelly D., Kaplan, Jason, Mi, Xinlei, Pro, Barbara, Winter, Jane N., Gordon, Leo I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928783/
https://www.ncbi.nlm.nih.gov/pubmed/36819145
http://dx.doi.org/10.1002/jha2.625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928783/
https://www.ncbi.nlm.nih.gov/pubmed/36819145
http://dx.doi.org/10.1002/jha2.625

Ejemplares similares